TY - JOUR
T1 - Single Point Insulin Sensitivity Estimator (SPISE) As a Prognostic Marker for Emerging Dysglycemia in Children with Overweight or Obesity
AU - Stein, Robert
AU - Koutny, Florian
AU - Riedel, Johannes
AU - Dörr, Natascha
AU - Meyer, Klara
AU - Colombo, Marco
AU - Vogel, Mandy
AU - Anderwald, Christian Heinz
AU - Blüher, Matthias
AU - Kiess, Wieland
AU - Körner, Antje
AU - Weghuber, Daniel
N1 - Funding Information:
We would like to thank all participating centers, especially the collaborating centers in LIFE Child (NCT02550236) and the Leipzig Childhood Obesity (NCT04491344). We acknowledge the support of the Scientific Publishing Service, provided by P. Voitl and E. Tomasco, on behalf of the Austrian Pediatric Society.
Funding Information:
This research was funded by the German Research Foundation for the Clinical Research Center “Obesity Mechanisms” (grant CRC1052 C05) and project KO3512/3-1; the Federal Ministry of Education and Research, Germany (grant 01GL1906 SUCCEED); and Leipzig Research Center for Civilization Diseases (LIFE Child), University of Leipzig, which was supported by the European Union, the European Regional Development Fund, and the Free State of Saxony within the framework of the excellence initiative. Clinical assessments of adults with overweight/obesity was facilitated by the clinical trial unit of the Helmholtz Institute for Metabolic, Obesity and Vascular Research of the Helmholtz Zentrum München at the University of Leipzig. Furthermore, AK acknowledges support by the German Diabetes Association (DDG), the JPI HDHL Metadis funded CarbHealth consortium (01EA1908B). R.S. was funded by the joint Clinician Scientist Programme of the Medical Faculty and the Helmholtz Institute for Metabolic, Obesity and Vascular Research of the Helmholtz Zentrum München at the University of Leipzig.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/1/7
Y1 - 2023/1/7
N2 - The single point insulin sensitivity estimator (SPISE) is a recently developed fasting index for insulin sensitivity based on triglycerides, high density lipoprotein cholesterol, and body mass index. SPISE has been validated in juveniles and adults; still, its role during childhood remains unclear. To evaluate the age- and sex-specific distribution of SPISE, its correlation with established fasting indexes and its application as a prognostic marker for future dysglycemia during childhood and adolescence were assessed. We performed linear modeling and correlation analyses on a cross-sectional cohort of 2107 children and adolescents (age 5 to 18.4 years) with overweight or obesity. Furthermore, survival analyses were conducted upon a longitudinal cohort of 591 children with overweight/obesity (1712 observations) with a maximum follow-up time of nearly 20 years, targeting prediabetes/dysglycemia as the end point. The SPISE index decreased significantly with age (-0.34 units per year, p < 0.001) among children and adolescents with overweight and obesity. Sex did not have an influence on SPISE. There was a modest correlation between SPISE and established fasting markers of insulin resistance (R = -0.49 for HOMA-IR, R = -0.55 for QUICKI-IR). SPISE is a better prognostic marker for future dysglycemia (hazard ratio (HR) 3.47, 95% confidence interval (CI) 1.60-7.51, p < 0.01) than HOMA-IR and QUICKI-IR (HR 2.44, 95% CI 1.24-4.81, p < 0.05). The SPISE index is a surrogate marker for insulin resistance predicting emerging dysglycemia in children with overweight or obesity, and could, therefore, be applied to pediatric cohorts that lack direct insulin assessment.
AB - The single point insulin sensitivity estimator (SPISE) is a recently developed fasting index for insulin sensitivity based on triglycerides, high density lipoprotein cholesterol, and body mass index. SPISE has been validated in juveniles and adults; still, its role during childhood remains unclear. To evaluate the age- and sex-specific distribution of SPISE, its correlation with established fasting indexes and its application as a prognostic marker for future dysglycemia during childhood and adolescence were assessed. We performed linear modeling and correlation analyses on a cross-sectional cohort of 2107 children and adolescents (age 5 to 18.4 years) with overweight or obesity. Furthermore, survival analyses were conducted upon a longitudinal cohort of 591 children with overweight/obesity (1712 observations) with a maximum follow-up time of nearly 20 years, targeting prediabetes/dysglycemia as the end point. The SPISE index decreased significantly with age (-0.34 units per year, p < 0.001) among children and adolescents with overweight and obesity. Sex did not have an influence on SPISE. There was a modest correlation between SPISE and established fasting markers of insulin resistance (R = -0.49 for HOMA-IR, R = -0.55 for QUICKI-IR). SPISE is a better prognostic marker for future dysglycemia (hazard ratio (HR) 3.47, 95% confidence interval (CI) 1.60-7.51, p < 0.01) than HOMA-IR and QUICKI-IR (HR 2.44, 95% CI 1.24-4.81, p < 0.05). The SPISE index is a surrogate marker for insulin resistance predicting emerging dysglycemia in children with overweight or obesity, and could, therefore, be applied to pediatric cohorts that lack direct insulin assessment.
KW - SPISE
KW - childhood obesity
KW - dysglycemia
KW - early-onset diabetes
KW - insulin resistance
KW - prediabetes
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85146764953&partnerID=8YFLogxK
U2 - 10.3390/metabo13010100
DO - 10.3390/metabo13010100
M3 - Journal article
C2 - 36677025
SN - 2218-1989
VL - 13
JO - Metabolites
JF - Metabolites
IS - 1
M1 - 100
ER -